期刊文献+

二甲双胍联合达英-35在治疗多囊卵巢综合征中的临床价值 被引量:1

下载PDF
导出
摘要 目的对二甲双胍联合达英-35 在多囊卵巢综合征患者治疗中的应用方法以及疗效进行详细探究.方法:选取本院 2017年 5 月至 2018 年 5 月收治的 50 例多囊卵巢综合征患者作为研究对象,根据治疗方式不同,将所有患者分为对照组 25 例以及观察组25 例.对于对照组患者,采用达英-35 治疗方案,对于观察组患者,采用二甲双胍联合达英-35 治疗方案.对两组患者临床疗效、治疗前后睾酮水平、黄体生成素水平、甘油三酯水平、总胆固醇水平进行统计比较.结果:观察组患者本次治疗总有效率为(24/25)96.0%,明显高于对照组患者本次治疗总有效率(20/25)80.0%;两组患者睾酮水平、黄体生成素水平、甘油三酯水平、总胆固醇水平均明显改善,同时,观察组患者改善情况明显优于对照组患者,差异显著,具有统计学意义,P〈0.05.结论:二甲双胍片和达英-35 被联合应用于治疗多囊卵巢综合症患者治疗中,能够有效改善患者睾酮水平、黄体生成素水平、甘油三酯水平、总胆固醇水平,提升治疗效果,值得推广应用.
出处 《医学食疗与健康》 2018年第7期80-81,共2页 Medical Diet and Health
  • 相关文献

参考文献4

二级参考文献30

  • 1谢幸,苟文丽.妇产科学[M].第8版.北京:人民卫生出版社,2013:258-264.
  • 2Zhao Y, Du B, Jiang X, et al. Effects of combining low- dose aspirin with a Chinese patent medicine on follicular blood flow and pregnancy outcome [ J ]. Mol Med Rep, 2014,10 (5) :2372- 2376.
  • 3Fauser B C, Tarlatzis B C, Rebar R W, et al. Consensus on women's health aspects of polycystic ovary syndrome ( P- COS): the Amsterdam ESHRE/ASRM-Sponsored 3rd P- COS Consensus Workshop Group[J]. Fertil Steril. , 2012, 97( 1 ) :28-38.
  • 4The Rotterdam ESHER/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus of diagnostic cri- teria and long-term health risks related to polycystic ovary syndrome(PCOS). Hum Reprod, 2004,19( 1 ) :41-47.
  • 5Salameh W A, Redor-Goldman M M, Clarke N J, et al. Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the National Institutes of Health 1990 criteria [ J ]. Fertil Steril, 2014, 101 ( 4 ) : 1135-1141.
  • 6Wang T, Guo Y, Song and W Huang. ' Association dipocyte factor level and insulin resistance in polycystic ovary syn- drome' [ J ]. Gynecological Endocrinology, 2011,27 ( 11 ) : p931- p934.
  • 7Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystie ovary syndrome [ J ]. Fertil Steril, 2008,89 (3) :505-522.
  • 8Dewailly D, Catteau-Jonard S, Reyss AC, et al. Oligo- anovulation with polyeystic ovaries but not overt hyperandro- genism[ J ]. J Clin Endocrinol Metab, 2006,91 (10) : 3922-3927.
  • 9Welt C K, Gudmundsson J A, Arsson G, et al. Characteri- zin discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on pheno- type and metabolic feature [ J]. J Clin Endocrinol Metab, 2006, 91:4842-4848.
  • 10Guastella E, Longo R A, Carmina E. Clinical and endo- crine characteristics of the main polycystic ovary syndrome phenotypes[ J ]. Fertil and Steril, 2010, 94 ( 6 ) : 2197 - 2201.

共引文献110

同被引文献6

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部